These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 9296083)

  • 1. [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
    Elkhaïli H; Pompei D; Peter JD; Linger L; Salmon J; Levêque D; Niedergang S; Salmon Y; Thierry RC; Monteil H; Jehl F
    Pathol Biol (Paris); 1997 May; 45(5):347-56. PubMed ID: 9296083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics in vivo and pharmacodynamics ex vivo/in vitro of meropenem and cefpirome in the Yucatan micropig model: continuous infusion versus intermittent injection.
    Elkhaïli H; Peter JD; Pompei D; Levless-Than-Or-Eq Slanteque D; Linger L; Salmon Y; Salmon J; Monteil H
    Clin Microbiol Infect; 1998 Jan; 4(1):18-26. PubMed ID: 11864228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro time-kill curves of cefepime and cefpirome combined with amikacin, gentamicin or ciprofloxacin against Klebsiella pneumoniae producing extended-spectrum beta-lactamase.
    Elkhaïli H; Kamili N; Linger L; Levêque D; Pompei D; Monteil H; Jehl F
    Chemotherapy; 1997; 43(4):245-53. PubMed ID: 9209781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of three new beta-lactams in the Yucatan micropig model administered by intravenous bolus injection and continuous infusion.
    Elkhaïli H; Levêque D; Peter JD; Salmon Y; Salmon J; Pompei D; Monteil H; Jehl F
    Int J Antimicrob Agents; 1997 Mar; 8(2):135-41. PubMed ID: 18611795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Kinetics of bactericidal activity of cefepime and cefpirome alone or combined with gentamicin, amikacin or ciprofloxacin against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae hyperproductive in cephalosporinase].
    Elkhaïli H; Pompei D; Linger L; Kamili N; Monteil H; Jehl F
    Pathol Biol (Paris); 1996 May; 44(5):367-73. PubMed ID: 8758478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach.
    Vourli S; Tsala M; Kotsakis S; Daikos GL; Tzouvelekis L; Miriagou V; Zerva L; Meletiadis J
    J Pharm Sci; 2016 Apr; 105(4):1513-8. PubMed ID: 27019965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Bowker KE; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
    Szabó D; Máthé A; Filetóth Z; Anderlik P; Rókusz L; Rozgonyi F
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1287-91. PubMed ID: 11257049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo.
    Mimoz O; Jacolot A; Padoin C; Caillon J; Louchahi K; Tod M; Samii K; Petitjean O
    J Antimicrob Chemother; 1997 Mar; 39(3):363-9. PubMed ID: 9096186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.
    Lubasch A; Ziege S; Brodersen B; Borner K; Koeppe P; Lode H
    Clin Microbiol Infect; 2003 Jul; 9(7):670-7. PubMed ID: 12925107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
    Mimoz O; Jacolot A; Padoin C; Tod M; Samii K; Petitjean O
    J Antimicrob Chemother; 1998 Mar; 41(3):367-72. PubMed ID: 9578163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance].
    Canis F; Cavallo JD; Husson MO
    Pathol Biol (Paris); 1997 May; 45(5):420-3. PubMed ID: 9296096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
    Georges B; Conil JM; Cougot P; Decun JF; Archambaud M; Seguin T; Chabanon G; Virenque C; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):360-9. PubMed ID: 16119511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.